Last reviewed · How we verify
NCT07126574: BioBurnSepsis
Evaluating the Accuracy of Multiple Blood Tests to Diagnose Sepsis in Adult Burn Patients
trial in Sepsis - to Reduce Mortality in the Intensive Care Unit in 165 participants. Not yet recruiting.
31 October 2026
Quick facts
| Lead sponsor | Dohern Kym |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 165 |
| Start date | 15 August 2025 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 October 2026 |
Conditions studied
- Sepsis - to Reduce Mortality in the Intensive Care Unit — all drugs for Sepsis - to Reduce Mortality in the Intensive Care Unit →
- Burns Involving 20% or More of Body Surface — all drugs for Burns Involving 20% or More of Body Surface →
Sponsor
Dohern Kym
Who can join
18 and older, any sex, with Sepsis - to Reduce Mortality in the Intensive Care Unit or Burns Involving 20% or More of Body Surface. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective diagnostic accuracy study evaluates the performance of presepsin and C-reactive protein (CRP) as early biomarkers for suspected sepsis in adult burn patients. From January 2021 to December 2022, 370 patients with ≥20% total body surface area burns admitted to the Burn Intensive Care Unit at Hallym University Hangang Sacred Heart Hospital were screened; 221 met inclusion criteria. At each clinical suspicion of sepsis (≥2 SIRS criteria), venous blood was drawn for simultaneous measurement of presepsin (via chemiluminescent immunoassay) and CRP (via immunoturbidimetric assay). Diagnostic accuracy will be quantified by sensitivity, specificity, positive/negative predictive values, and area under the ROC curve. The goal is to determine whether presepsin outperforms CRP for early sepsis detection in severe burn patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07126574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis - to Reduce Mortality in the Intensive Care Unit
Currently open trials in the same condition.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT06766461 — Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis · Phase 4 · recruiting
- NCT06891599 — ROTEM in Sepsis Trauma Outcome in Intensive Care · recruiting
Other Dohern Kym trials
Trials by the same sponsor.
- NCT07060560 — Presepsin Diagnostic Performance in Severe Burn Sepsis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07126574 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dohern Kym
- Last refreshed: 17 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07126574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing